Expanding the Capabilities of Modern Size-Exclusion Chromatography with Advanced Particle and Column Hardware

Register Free: https://www.biopharminternational.com/bp_w/particle

Event Overview:

Improvements in size-exclusion chromatography (SEC) particle technologies in the last decade have given scientists a wide selection of high efficiency SEC columns. As SEC columns have asymptotically approached maximum plate counts at reasonable operating pressures, the most significant improvements to be gained for these separations are improvements in the inertness of not only the packed particles but also the column hardware. This presentation will review how new hydrophilic surfaces combined with advances in particle technology result in significantly decreased non-desired interactions with proteins and other biomolecules, specifically:

• Increased SEC capability and long-term stability to evaluate protein and other biomolecule size variants using SEC with buffers over a wide pH range (2.5 to 8.0) including buffers at or near physiological pH and ionic strength
• Improved platform analytical SEC method versatility on ultra-performance liquid chromatography (UPLC) or high-performance liquid chromatography instrumentation (HPLC)
• Column options enabling exceptionally high resolution or high sample throughput SEC analyses
• Effective use of volatile salt concentrations for optimal SEC-MS methods

Key Learning Objectives:

• Understanding the key characteristics of protein and other biomolecule SEC separations
• Learning about new SEC technologies and the performance differences of newly developed SEC columns in comparison to traditional SEC fast protein liquid chromatography, HPLC, and UHPLC SEC columns
• An introduction to rapid method development, and simplified deployment in addition to demonstrated column stability when using mobile phases buffered at a physiologically relevant pH

Who Should Attend:

Lab scientists involved in the development or deployment of SEC separations for the analyses of proteins, conjugated protein, other biomolecules, or macromolecules prone to ionic or hydrophobic interactions.

Speakers

Stephan Koza
Consulting Scientist
Waters Corporation

Stephan M. Koza, PhD, consulting scientist for Waters Corporation, has worked at Waters Corporation for nine years and leads an applications group that focuses on the use of LC, LC-MS[MR1], and sample preparation chemistries and columns for the analysis of biomolecules. Prior to Waters, Stephan worked with Genetics Institute, Wyeth, and Pfizer on biopharmaceutical characterization and analytical method development.

Register free: https://www.biopharminternational.com/bp_w/particle​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

​